Monalizumab Biosimilar - Ultra Low Endotoxin

Monalizumab Biosimilar - Ultra Low Endotoxin, Human IgG4

Target: NKG2A

Specificity: Detects human CD159a. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Monalizumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: RUO monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response.

Concentration: 5mg/ml

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 0.1 EU/mg as determined by the LAL method

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• SKU: ICH5017UL-100mg
• Manufacturer: Ichorbio
• Manufacturer SKU: ICH5017UL-100mg
• Package Unit: 100mg
• Quantity Unit: STK
• Reactivity: Human
• Clonality: Monoclonal
• Application: Functional Assay
• Isotype: Human IgG4